Nasdaq:US$15.39 (+0.31) | HKEX:HK$23.72 (-0.56) | AIM:£2.29 (-0.03)
Search
Announcements
123456
7
89101112131415161718
found Documents: 861
Announcements & Press Releases, Oncology / Immunology | 26 Aug 2021

HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer
Hong Kong, Shanghai & Florham Park, NJ — Thursday, August 26, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) has initiated a Phase Ib/II study of fruquintinib in combination with BeiGene’s tislelizumab in patients
Read More
LSE RNS Announcement (PDF)HKEX – Voluntary Announcement (PDF)
Announcements & Press Releases, Group | 23 Aug 2021

HUTCHMED Selected as Constituent of Certain Hang Seng Indexes
Hong Kong, Shanghai & Florham Park, NJ — Monday, August 23, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that HUTCHMED has been selected as a constituent stock of several indexes administered by Ha
Read More
HKEX – Voluntary Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 17 Aug 2021

Electronic Communication of Corporate Information
Hong Kong, Shanghai & Florham Park, NJ — August 17, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces that it has written to its shareholders regarding its intention to adopt electronic c
Read More
LSE RNS Announcement (PDF)Letter to UK shareholders (PDF)
Announcements & Press Releases, Regulatory Notice | 17 Aug 2021

Election of language and means of receipt of corporate communications
HKEX Announcement (PDF)Letter and reply form to new registered shareholders (PDF)Notification letter and request form to non-registered holders (PDF)
Announcements & Press Releases, Oncology / Immunology | 9 Aug 2021

HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
- Collaboration designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED’s novel oncology medicines portfolio - - Epizyme to receive US$25 million upfront payment and up to US$285 million in potential milesto
Read More
LSE RNS Announcement (PDF)HKEX - Voluntary Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 4 Aug 2021

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Jul 2021

Total Voting Rights
Hong Kong, Shanghai, & Florham Park, NJ — Friday, July 30, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) hereby notifies the market that as at July 30, 2021, the issued share capital of HUTCHMED consisted of 864,11
Read More
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 28 Jul 2021

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
HKEX Announcement (PDF)
Announcements & Press Releases, Group | 28 Jul 2021

HUTCHMED Reports 2021 Interim Results and Provides Business Updates
ELUNATE® in-market sales1 rose 186%, reflecting impact of in-house sales force Received 1st approval in China for ORPATHYS® and 2nd approval in China for SULANDA® U.S. and E.U. applications for surufatinib both accepted Raised $615m2 gross pr
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 28 Jul 2021

HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer
— Follows multiple Phase II studies of ORPATHYS® in Asia including VIKTORY, which reported an 50% objective response rate (ORR) in gastric cancer patients whose tumors harbor MET amplification — Hong Kong, Shanghai & Florham Park, NJ —
Read More
LSE RNS Announcement (PDF)HKEX - Voluntary Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 23 Jul 2021

Stabilizing Actions and End of Stabilization Period in connection with the Global Offering
Hong Kong, Shanghai & Florham Park, NJ — Friday, July 23, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces that the stabilization period in connection with the Global Offering ended on J
Read More
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 16 Jul 2021

TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:
Read More
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 16 Jul 2021

HUTCHMED’s Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency
– EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors –   –  Expands potential global reach of surufatinib, in addition to China where it is already launched, and in the U.S. where it is under review for
Read More
HKEX - Voluntary Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 14 Jul 2021

TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:
Read More
HKEX Overseas Regulatory Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 13 Jul 2021

First Commercial Sale of ORPATHYS® in China Triggering a US$25 million Milestone Payment from AstraZeneca
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, July 13, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces the first commercial sale in China of ORPATHYS® (savolitinib), HUTCHMED’s oral, potent, and high
Read More
HKEX - Voluntary Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Group | 12 Jul 2021

HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global Offering
Hong Kong, Shanghai, & Florham Park, NJ — Monday, July 12, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM, HKEX:13) today announces the full exercise of the over-allotment option of the Global Offering. Th
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 7 Jul 2021

Monthly Return
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 6 Jul 2021

HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL-295 in Patients with Advanced Solid Tumors in China
Hong Kong, Shanghai and Florham Park, NJ — Tuesday, July 6, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) has initiated a Phase I study of HMPL‑295, its investigative and highly selective oral inhibitor of ERK, which
Read More
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 Jul 2021

TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:
Read More
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)
Announcements & Press Releases, Group | 2 Jul 2021

HUTCHMED to Announce 2021 Half-Year Financial Results
Hong Kong, Shanghai & Florham Park, NJ — Friday, July 2, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will be announcing its interim results for the six months ended June 30, 2021 on Wednesday, July 28, 2021 at 12:
Read More
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 1 Jul 2021

U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
– U.S. FDA has assigned a target action date of April 30, 2022 – – If approved, surufatinib would be HUTCHMED’s first novel oncology drug marketed outside of China –   Hong Kong, Shanghai & Florham Park, NJ — Thursday,
Read More
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Jun 2021

Total Voting Rights
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, June 30, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) hereby notifies the market that as at June 30, 2021, the issued share capital of HUTCHMED consisted of 848,51
Read More
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Jun 2021

Holdings in Company
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, June 30, 2021:  HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM, HKEX: 13) announces that, in connection with its global offering (the "Global Offering") of 104,
Read More
HKEX Overseas Regulatory Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Group | 30 Jun 2021

HUTCHMED Announces the Closing of the Global Offering and the Primary Listing in Hong Kong
Hong Kong, Shanghai, & Florham Park, NJ — Wednesday, June 30, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces the listing of its ordinary shares (“Shares”) on the Main Board of the Stoc
Read More
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Jun 2021

Blocklisting Six Monthly Return
Hong Kong, Shanghai, & Florham Park, NJ — Tuesday, June 29, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) announces the following blocklisting six monthly return:   1. Name of applicant:
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Jun 2021

List of Directors and Their Roles and Functions
Download List of Directors and Role and Function (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Jun 2021

ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS
HKEX Announcement (PDF)
Announcements & Press Releases, Group | 23 Jun 2021

HUTCHMED Announces Pricing of Global Offering
Hong Kong, Shanghai, & Florham Park, NJ — Wednesday, June 23, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces the pricing of its global offering (the “Global Offering”) of 104,000,000 n
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 22 Jun 2021

HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations
– First selective MET inhibitor approval in China in this setting – – First regulatory approval for the oral, potent and selective MET tyrosine kinase inhibitor –   Hong Kong, Shanghai & Florham Park, NJ —Tuesday, June 22, 202
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 18 Jun 2021

HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda® in China) for Advanced Pancreatic Neuroendocrine Tumors
– Second New Drug Application (“NDA”) approved for Sulanda in China – – The pivotal Phase III SANET-p trial demonstrated surufatinib reduced risk of progression or death by 51% in patients with advanced pancreatic NET –   Hong K
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 18 Jun 2021

Disclosure Update
Hong Kong, Shanghai, & Florham Park, NJ — Friday, June 18, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today filed the Post Hearing Information Pack (the “PHIP”) with the Stock Exchange of Hong Kon
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 18 Jun 2021

HUTCHMED Launches Hong Kong Initial Public Offering
Hong Kong, Shanghai, & Florham Park, NJ — Friday, June 18, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces the launch of its Hong Kong public offering (the “Hong Kong Public Offering”),
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 20 May 2021

HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program
– HUTCHMED will review these highlights as part of its company update audio call and webcast on Wednesday, May 26 at 8 a.m. EDT to discuss data disclosures, its PD-1/L1 combination study strategy and provide a corporate update –   Hong Kong,
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 17 May 2021

Save the date: HUTCHMED to Host Company Update on R&D, Commercial and ASCO Data For Analysts and Investors
– HUTCHMED will hold a webcast on Wednesday, May 26 at 8 a.m. EDT to provide updates on recent progress and upcoming milestones –   Hong Kong, Shanghai & Florham Park, NJ — Monday, May 17, 2021: HUTCHMED (China) Limited (“HUTCHME
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 7 May 2021

HUTCHMED to Attend Upcoming Investor Conferences
Hong Kong, Shanghai & Florham Park, NJ — Friday, May 7, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of HUTCHMED, will participate in a virtual fireside chat a
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 4 May 2021

Change of Company Name
Hong Kong, Shanghai, & Florham Park, NJ — Tuesday, May 4, 2021: HUTCHMED (China) Limited (Nasdaq/AIM: HCM), formerly known as Hutchison China MediTech Limited, announces that, further to its “Results of Annual General Meeting” announcement
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 3 May 2021

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
– First NDA submission by HUTCHMED in the U.S.; product launch preparations underway –   Hong Kong, Shanghai & Florham Park, NJ — Monday, May 3, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces th
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Apr 2021

HUTCHMED Initiates Phase II Registration Study of HMPL-689 in Patients with Follicular Lymphoma and Marginal Zone Lymphoma in China
— Single-arm study in ~180 patients, with ORR as primary endpoint — — Relapsed/refractory FL and MZL constitute approximately 25% of all NHL — — HMPL-689 trials are also underway in these and other NHL subtypes in the U.S., Europe an
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 28 Apr 2021

Results of Annual General Meeting
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, April 28, 2021: Hutchison China MediTech Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual G
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 23 Apr 2021

Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ: Friday, April 23, 2021: Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on April 2
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 14 Apr 2021

Notification of Dilution of Voting Rights
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, April 14, 2021:  Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited (“CK Hutchison”) shareholding[1] in HUTCHMED remains unc
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 8 Apr 2021

HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   Hong Kong, Shanghai & Florham Park, NJ — Thu
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Mar 2021

Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme
Hong Kong, Shanghai, & Florham Park, NJ: Monday, March 29, 2021: Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) announces that on March 26, 2021, it granted conditional awards (“LTIP Awards”) under the Long Term Incentive
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Mar 2021

HUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological Malignancies
— HMPL-306 is the sixth innovative oncology drug candidate discovered in house by HUTCHMED to enter into global development —   Hong Kong, Shanghai & Florham Park, NJ — Monday, March 29, 2021: Hutchison China MediTech Limited (“HUT
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 26 Mar 2021

2020 Annual Report and Notice of Annual General Meeting
Hong Kong, Shanghai, & Florham Park, NJ: Friday, March 26, 2021: Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces that its 2020 Annual Report together with the Notice of Annual General Meeting and the Form of Pr
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 24 Mar 2021

HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million
– Allows focus on China and global clinical development and market launches of key Oncology/Immunology assets –   Hong Kong, Shanghai & Florham Park, NJ –– Wednesday, March 24, 2021: Hutchison China MediTech Limited (“HUTCHME
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 24 Mar 2021

HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 24, 2021: Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) has initiated a Phase Ib/II study of surufatinib in combination with BeiGene’s tislelizumab in patients w
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 10 Mar 2021

Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, March 10, 2021: Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) announces that following the announcement of the 2020 annual results of HUTCHMED on March 4, 2021, 2,656 Ameri
Read More
View Announcement (PDF)
Group | 4 Mar 2021

Chi-Med becomes HUTCHMED
Today, we begin consolidating the two corporate identities that we have used since our inception.  Hutchison China MediTech, or Chi-Med, has been used as our group identity, while Hutchison MediPharma has been the identity of our novel drug R&D
Read More
Announcements & Press Releases, Group | 4 Mar 2021

Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity
Company to Host Annual Results Call & Webcast Today at 1 p.m. GMT / 8 a.m. EST / 9 p.m. HKT  Hong Kong, Shanghai & Florham Park, NJ––Thursday, March 4, 2021:  Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM), a
Read More
View Announcement (PDF)
123456
7
89101112131415161718